for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Atara Biotherapeutics Inc

ATRA.OQ

Latest Trade

17.09USD

Change

-0.92(-5.11%)

Volume

322,214

Today's Range

16.85

 - 

18.21

52 Week Range

11.81

 - 

28.16

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.01
Open
18.19
Volume
322,214
3M AVG Volume
16.78
Today's High
18.21
Today's Low
16.85
52 Week High
28.16
52 Week Low
11.81
Shares Out (MIL)
88.42
Market Cap (MIL)
1,511.05
Forward P/E
-4.96
Dividend (Yield %)
--

Next Event

Q4 2021 Atara Biotherapeutics Inc Earnings Release

Latest Developments

More

Atara Biotherapeutics Inc And Pierre Fabre Enter Strategic Collaboration To Commercialize Tabelecleucel (Tab-Cel)

Atara Biotherapeutics Reports Q1 Loss Per Share of $0.86

Atara Biotherapeutics Reports Qtrly Loss Per Share Of $0.95

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. is engaged in developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease. The Company’s pipeline products include Tab-cel and ATA188, as well as ATA2271, ATA3271 and ATA3219 under CAR T Programs. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. The Company’s ATA188 is a T-cell immunotherapy targeting EBV antigens for the treatment of multiple sclerosis. Its ATA2271 is an autologous chimeric antigen receptors (CAR) T immunotherapy targeting solid tumors expressing the tumor antigen mesothelin.

Industry

Biotechnology & Drugs

Contact Info

611 Gateway Blvd Ste 900

SOUTH SAN FRANCISCO, CA

94080-7015

United States

+1.650.2788930

http://www.atarabio.com/

Executive Leadership

Ronald C. Renaud

Chairman of the Board

Pascal Touchon

President, Chief Executive Officer, Director

Utpal Koppikar

Chief Financial Officer, Senior Vice President

Joseph Newell

Chief Operating Officer, Executive Vice President

Jakob Dupont

Executive Vice President, Global Head of Research and Development

Key Stats

1.82 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-5.270

2019

-5.670

2020

-4.150

2021(E)

-3.447
Price To Earnings (TTM)
--
Price To Sales (TTM)
118.12
Price To Book (MRQ)
4.87
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-89.49
Return on Equity (TTM)
-76.71

Latest News

Latest News

Bayer accelerates cell and gene therapy drive with Atara deal

Bayer AG has struck a deal with Atara Biotherapeutics to jointly work on Atara's CAR-T cell anti-tumour treatments, as the German group firms up its commitment to build a specialist cell and gene therapy development platform.

CORRECTED-UPDATE 1-Bayer signs deal to sell Atara's experimental cancer therapy

Germany's Bayer AG said on Monday it has signed an agreement with Atara Biotherapeutics Inc to sell the U.S. drugmaker's experimental cancer therapy, in a move that would expand its oncology pipeline.

CORRECTED-Bayer signs agreement to sell Atara's cancer therapy

Bayer AG said on Monday it has signed an agreement with Atara Biotherapeutics Inc to sell Atara's experimental cancer therapy.

BRIEF-Atara Biotherapeutics Says First Patient Enrolled In Randomized Placebo-Controlled Study Of Allogeneic T-Cell Therapy ATA188

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN RANDOMIZED PLACEBO-CONTROLLED STUDY OF ALLOGENEIC T-CELL THERAPY ATA188 IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics Announces Its 2020 Annual Meeting Of Stockholders Will Be Held On June 16, 2020 In Virtual Format

* ATARA BIOTHERAPEUTICS ANNOUNCES ITS 2020 ANNUAL MEETING OF STOCKHOLDERS WILL BE HELD ON JUNE 16, 2020 IN VIRTUAL FORMAT Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics Announces Pricing Of $175.5 Million Public Offering

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF $175.5 MILLION PUBLIC OFFERING

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock And Pre-Funded Warrants

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics Believes It Remains On Track To Initiate A Tab-cel BLA Submission For Patients With EBV+ Ptld In Second Half Of 2020

* ATARA BIOTHERAPEUTICS INC - BELIEVES IT REMAINS ON TRACK TO INITIATE A TAB-CEL BLA SUBMISSION FOR PATIENTS WITH EBV+ PTLD IN SECOND HALF OF 2020

BRIEF-Atara Biotherapeutics Qtrly Loss Per Share $1.36

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT CLINICAL, OPERATIONAL AND STRATEGIC PROGRESS

BRIEF-Atara Biotherapeutics Appoints Pascal Touchon As Chief Executive Officer

* ATARA BIOTHERAPEUTICS APPOINTS PASCAL TOUCHON PRESIDENT, CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up